Core Insights - GENFIT reported its third quarter 2025 financial results, highlighting a focus on developing treatments for rare and life-threatening liver diseases, particularly Acute on-Chronic Liver Failure (ACLF) [1][22] Financial Performance - As of September 30, 2025, the company's cash and cash equivalents increased to €119.0 million from €107.5 million as of June 30, 2025, and €81.8 million as of December 31, 2024 [2][10] - Revenue for the first nine months of 2025 was €39.2 million, a decrease from €59.7 million in the same period of 2024 [5] - The revenue was primarily driven by a Licensing and Collaboration Agreement with Ipsen, which included €12.6 million in royalty revenue and €26.5 million in milestone revenue from pricing and reimbursement approvals for Iqirvo (elafibranor) in three major European markets [6][10] Pipeline Development - The company is advancing its ACLF pipeline, with several programs in various stages of development: - G1090N is undergoing a Phase 1 First-in-Human study, with safety data expected by the end of 2025 [7] - SRT-015 aims to improve formulation for increased exposure, with a potential first-in-human trial in the second half of 2026 [7] - CLM-022 is in experiments to confirm therapeutic efficacy, with a first-in-human trial potentially starting in the first half of 2027 [8] - VS-02-HE is being developed as an oral formulation targeting gut ammonia production, with a first-in-human trial expected in the second half of 2027 [9] - GNS561 is in a Phase 1b clinical trial for cholangiocarcinoma, with data readout expected by the end of 2025 [11] Market Position - Iqirvo (elafibranor) continues to show solid growth in both U.S. and European markets for Primary Biliary Cholangitis (PBC), as reported by Ipsen [13]

BYD introduced its new ATTO 2 DM-i Super Hybrid in Barcelona, marking another step in the company’s rapid expansion across Europe and its strategy to offer electrified mobility tailored to the continent’s everyday driving habits. BARCELONA, Spain, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BYD introduced its new ATTO 2 DM-i Super Hybrid in Barcelona, marking another step in the company’s rapid expansion across Europe and its strategy to offer electrified mobility tailored to the continent’s everyday driving ...

NORBIT today announces that its segment Connectivity has received a new order for deliveries to the leading European Electronic Toll Service (EETS) provider Toll4Europe of GNSS On-Board Units. Deliveries are scheduled for first half of 2026. The total order is estimated to NOK 160 million. “We are proud to be given the trust from Europe’s leading tolling service provider. This repeat order demonstrates the strength of our ability to deliver tailored technology and our strategy to act as a technology partne ...

RESTON, Va., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC) is scheduled to issue its third quarter fiscal year 2026 results before market open on Thursday, December 4, 2025. SAIC executive management will discuss operational and financial results in a conference call beginning at 10:00 a.m. Eastern time, following the issuance of the company’s earnings press release.  The conference call will be webcast simultaneously to the public through a link on the Investors ...

Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Select Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The ...

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in lung and MSS colorectal cancer models NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune ...

JIANGYIN, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Li Bang International Corporation Inc. ("Li Bang International") and its subsidiaries (collectively, the "Company," "we," "us," "our company," or "Li Bang") (Nasdaq: LBGJ), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced the listing of the new Class A ordinary shares, par value US$0.0001 per share (“Class A Ordinary Shares), on the Nasdaq Capital Market in substitution ...

Aspo Plc ANNOUNCEMENT 20.11.2025 Aspo Plc: Share repurchase 20.11.2025 In the Helsinki Stock Exchange Trade date 20.11.2025 Bourse trade Buy Share ASPO Amount 2 312SharesAverage price/ share 6,6827EURTotal cost 15 450,40EUR Aspo Plc now holds ...

New luxury home collection features resort-style amenities and sophisticated designs in a prime location near downtown RaleighRALEIGH, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced its Regency at Olde Towne 55+ active-adult community in Raleigh, North Carolina is now offering a new phase of home sites as part of its Excursion Collection. Situated within the Olde Towne master plan, this community blends the vibrancy of ci ...

Helstu atriði úr fjárhagsuppgjöri 3F 2025 Vörusala var 111 m€ á fjórðungnum samanborið við 110 m€ á þriðja fjórðungi 2024Hagnaður var 29 m€ á fjórðungnum samanborið við 19 m€ á þriðja fjórðungi 2024EBITDA var 42 m€ og EBITDA hlutfall 37,3%Eignir hafa lækkað um 13 m€ frá áramótum og voru 983 m€ í lok tímabilsinsEigið fé þann 30. september 2025 var 505 m€ og eignfjárhlutfall 51,4% Guðmundur Kristjánsson, forstjóri: „Afkoma þriðja fjórðungs er góð og eru það tveir þættir sem skipta mestu máli. Veiðar og vinnsl ...